36,237 Shares in Kymera Therapeutics, Inc. $KYMR Bought by Legal & General Group Plc

Legal & General Group Plc acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 2nd quarter, Holdings Channel reports. The fund acquired 36,237 shares of the company’s stock, valued at approximately $4,155,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in KYMR. Merck & Co. Inc. bought a new position in shares of Kymera Therapeutics during the 2nd quarter worth approximately $88,544,161. Deutsche Bank AG bought a new stake in shares of Kymera Therapeutics during the 2nd quarter worth approximately $12,161,000. Eagle Health Investments LP acquired a new stake in shares of Kymera Therapeutics in the 2nd quarter valued at approximately $19,052,000. BlackRock Inc. bought a new position in shares of Kymera Therapeutics in the second quarter valued at $635,067,000. Finally, Maven Securities LTD bought a new position in shares of Kymera Therapeutics in the fourth quarter valued at $1,167,000.

Insider Buying and Selling

In related news, insider Brian Adams sold 6,371 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $116.83, for a total transaction of $744,323.93. Following the transaction, the insider directly owned 50,254 shares of the company’s stock, valued at $5,871,174.82. This trade represents a 11.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 50,000 shares of Kymera Therapeutics stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $119.00, for a total value of $5,950,000.00. Following the sale, the chief executive officer owned 666,568 shares in the company, valued at $79,321,592. This trade represents a 6.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,594,000 shares of company stock worth $386,928,106 over the last ninety days. Insiders own 15.98% of the company’s stock.

Kymera Therapeutics Stock Performance

Shares of KYMR stock opened at $117.39 on Friday. The company has a market cap of $9.76 billion, a P/E ratio of -36.23 and a beta of 1.96. The stock has a 50 day simple moving average of $114.16 and a two-hundred day simple moving average of $94.90. Kymera Therapeutics, Inc. has a fifty-two week low of $42.22 and a fifty-two week high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The company had revenue of $65.00 million during the quarter, compared to the consensus estimate of $32.78 million. During the same period last year, the business posted ($0.95) EPS. The firm’s revenue for the quarter was up 465.2% compared to the same quarter last year. On average, research analysts predict that Kymera Therapeutics, Inc. will post -3.78 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on KYMR shares. Truist Financial increased their price target on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Bank of America lifted their price objective on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Wells Fargo & Company upped their price target on shares of Kymera Therapeutics from $116.00 to $151.00 and gave the company an “overweight” rating in a research note on Thursday, August 27th. Loop Capital set a $97.00 price objective on shares of Kymera Therapeutics in a research note on Monday, June 8th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $134.00 price target on shares of Kymera Therapeutics in a research note on Thursday, June 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $128.70.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.